Results 241 to 250 of about 8,424 (263)

Intracoronary eptifibatide with vasodilators to prevent no-reflow in diabetic STEMI with high thrombus burden. A randomized trial.

Revista Española de Cardiología, 2022
M. Hamza, I. Elgendy
semanticscholar   +1 more source

The role of eptifibatide in patients undergoing percutaneous coronary intervention

Expert Opinion on Pharmacotherapy, 2007
Glycoprotein (GP) IIb/IIIa receptor antagonists inhibit the binding of ligands to activated platelet GP IIb/IIIa receptors and, therefore, prevent the formation of platelet thrombi. They have been extensively studied in patients undergoing percutaneous coronary intervention (PCI).
openaire   +3 more sources

Surface modification of polyurethane with eptifibatide-loaded degradable nanoparticles reducing risk of blood coagulation.

Colloids and Surfaces B: Biointerfaces, 2021
K. Reczyńska, R. Major, M. Kopernik, E. Pamuła, G. Imbir, H. Plutecka, F. Bruckert, M. Surmiak   +7 more
semanticscholar   +1 more source

Association of eptifibatide and acute profound thrombocytopenia

The American Journal of Cardiology, 2001
Bruce N. Brent, Richard Hongo
openaire   +3 more sources

Eptifibatide

Reactions weekly, 2021

semanticscholar   +2 more sources

Eptifibatide/verapamil

Reactions weekly, 2021

semanticscholar   +1 more source

Eptifibatide in Acute Coronary Syndromes

New England Journal of Medicine, 1999
openaire   +3 more sources

Eptifibatid und perkutane koronare Intervention

Herz, 2004
openaire   +3 more sources

Eptifibatide

Reactions Weekly, 2004
openaire   +1 more source

Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion.

Journal of Stroke & Cerebrovascular Diseases, 2020
N. Osteraas, R. Crowley, N. Panos, R. Dafer   +3 more
semanticscholar   +1 more source